ChromoGenics AB (publ) announces allocation in directed share issue
On 5 March 2024 ChromoGenics AB (publ) ("ChromoGenics" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the extraordinary general meeting, on a directed issue of 2,505,885 shares in a total amount of SEK 16 million (the "Directed Issue"). The subscription price amounted to SEK 6.44 per share and was determined based on an accelerated bookbuilding procedure carried out by Vator Securities AB (acting as Sole Bookrunner). The subscribers in the Directed Issue consist of existing shareholders, including the Company's two largest